Class 4 Caution in Use
Aventis Pharma Limited t/a Sanofi has informed the MHRA that a change to the Patient Information Leaflet concerning possible side effects for Rifadin (rifampicin) 150mg Capsules has not been implemented by the required timeline.
Please visit the: MHRA website for more details on this drug alert.
The affected products' details are as follows:
PIP Code | Product Description | Supplier | Affected Batch |
---|---|---|---|
240838 | RIFADIN CAP 150MG | SANOFI | 9G020A |
For medical information enquiries, please contact Sanofi Medical Information, Tel +44 (0) 845 372 7101; email uk-medicalinformation@sanofi.com.
Recipients of this Drug Alert should bring it to the attention of relevant contacts.
Please note that this is a caution in use only and we are not accepting stock returns.
If you have any questions, then please contact your local Service Centre Customer Services team.